personalizing therapy for high-risk hr breast cancer: insights from monarche and natalee trials
Published 3 months ago • 56 plays • Length 1:32Download video MP4
Download video MP3
Similar videos
-
2:30
monarche: abemaciclib and adjuvant endocrine therapy for high-risk hr early breast cancer
-
4:03
monarche 4-year: abemaciclib endocrine therapy for hr , her2-, node-positive, high-risk early bc
-
1:26
monarche: investigating adjuvant abemacicilib for high-risk hr breast cancer
-
1:48
natalee and monarche: ribociclib and abemaciclib in hr /her2- breast cancer
-
1:30
exploring endocrine therapy innovations for high-risk hormone receptor-positive breast cancer
-
2:10
monarche: adjuvant abemaciclib endocrine therapy in patients with hr , her2- high-risk ebc
-
29:10
adjuvant abemaciclib/ribociclib #monarche/natalee #best treatment for breast cancer #cdk 4/6 -cure
-
1:08
4-year monarche results: increasing benefits with abemaciclib et for er /her2- high-risk early bc
-
4:28
asco 2023 highlights in breast cancer: natalee, monarche, and penelope-b
-
2:35
treatment options for high risk early breast cancer
-
1:12
monarche: adjuvant abemaciclib in hr breast cancer
-
1:24
advancing personalized breast cancer treatment: insights from ecog-acrin e4112 and adaptcycle trials
-
5:01
cdk4/6 inhibitors: sequencing endocrine therapy for metastatic breast cancer
-
1:48
top breast cancer abstracts at asco 2023: natalee and phergain
-
0:38
inclusion criteria for natalee trial - evaluating importance of ajuvant ribociclib #oncology #cancer
-
5:06
safety outcomes in the phase iii monarche trial of abemaciclib et in hr , her2- breast cancer
-
3:06
age-stratified findings from the monarche trial of abemaciclib in breast cancer
-
4:19
monarche results: abemaciclib plus endocrine therapy in high-risk early breast cancer
-
2:23
natalee: ribociclib nsai as adjuvant treatment in patients with hr /her2− early breast cancer